Yongxian Hu

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL

Jiqin Zhang, Yongxian Hu, Jiaxuan Yang et al. · Nature · 2022 · 353 citations · Full text

Life Sciences, Immunology, Oncology +9

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu, Yali Zhou, Mingming Zhang et al. · Clinical Cancer Research · 2021 · 274 citations · Full text

Life Sciences, Immunology, Oncology +17

Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study

Yongxian Hu, Yali Zhou, Mingming Zhang et al. · Cell Research · 2022 · 190 citations · Full text

Medicine, Hematology, Immunology +16

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial

Mingming Zhang, Guoqing Wei, Linghui Zhou et al. · The Lancet Haematology · 2023 · 159 citations

Medicine, Immunology, Oncology +14

Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu, Zhao Wu, Yi Luo et al. · Clinical Cancer Research · 2016 · 134 citations

Life Sciences, Oncology, Pharmacology +17